•  
  •  
 

Corresponding Author

Ashrakat Galal

Subject Area

Hepatology and GIT

Article Type

Review Article

Abstract

In children, hepatitis C virus (HCV) remains a serious health concern, especially those receiving cancer treatment, where repeated blood transfusions and immunosuppression significantly increase the risk of infection. The use of direct-acting antivirals (DAAs) represents a turning point in HCV management, delivering high cure rates with fewer side effects than previous therapies. In this review, we explore the latest insights into HCV epidemiology, transmission, and pathophysiology in pediatric patients, with particular attention to those facing malignancy. We will discuss the mechanisms of action, approved treatment regimens, and safety profiles of DAAs, focusing on combinations like sofosbuvir/ledipasvir in the oncology setting. The review also highlights clinical challenges, practical treatment considerations, and areas where further research is needed. Early screening and timely incorporation of antiviral therapy into cancer care pathways are essential steps toward improving long-term outcomes for this high-risk group.

Creative Commons License

Creative Commons Attribution 4.0 International License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Share

COinS